Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FOPO nets $87.3mm for Orexigen

Executive Summary

Orexigen Therapeutics Inc. (developing obesity treatments) has netted $87.3mm through the public sale of 5.6mm units at $15.94. Each unit consists of one common share and a ten-year warrant to buy ten shares of common stock at $1.45 apiece.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies